Skip to content

Clinical trials

Leukemia, Promyelocytic, Acute trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Promyelocytic, Acute Country / region: Germany Clear all

11 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20041
20051
20071
20091
20111
20141
20161
20191

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status5
Completed3
Terminated2
Recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Gruppo Italiano Malattie EMatologiche dell'Adulto2
Technische Universität Dresden2
Aegera Therapeutics1
Associazione Italiana Ematologia Oncologia Pediatrica1
European Organisation for Research and Treatment of Cancer - EORTC1
Fred Hutchinson Cancer Center1
German AML Cooperative Group1
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH1
Skyline Diagnostics BV1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Promyelocytic, Acute11
Leukemia4
Leukemia, Myeloid, Acute2
Anemia, Refractory, with Excess of Blasts1
Blast Crisis1
Burkitt Lymphoma1
Dendritic Cell Sarcoma, Interdigitating1
Hodgkin Disease1
Leukemia, Lymphocytic, Chronic, B-Cell1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive1

Trials

Showing 26 to 11 of 11. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.